Adaptive Biotechnologies Corp (ADPT) stock
ADPTNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$28.49+0.62 (+2.22%)
Close on Nov 17, 2026Market cap $4.55BP/E –Yield –
Adaptive Biotechnologies operating cash flow
Operating cash flow is the cash the business generates from its day-to-day operations.
Adaptive Biotechnologies's operating cash flow for the twelve months ending Jun 30, 2026 was -$21.01M. For fiscal 2025 it was -$45.99M. The highest annual figure on record is $205.40M in fiscal 2019.
Annual operating cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$45.99M | – |
| FY2024 | Dec 31, 2024 | -$95.21M | – |
| FY2023 | Dec 31, 2023 | -$156.32M | – |
| FY2022 | Dec 31, 2022 | -$183.95M | – |
| FY2021 | Dec 31, 2021 | -$192.73M | – |
| FY2020 | Dec 31, 2020 | -$149.68M | -172.9% |
| FY2019 | Dec 31, 2019 | $205.40M | – |
| FY2018 | Dec 31, 2018 | -$32.26M | – |
| FY2017 | Dec 31, 2017 | -$34.86M | – |
Quarterly operating cash flow
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$6.40M | – |
| Q1 FY2026 | Mar 31, 2026 | -$9.54M | – |
| Q4 FY2025 | Dec 31, 2025 | $2.06M | – |
| Q3 FY2025 | Sep 30, 2025 | -$7.13M | – |
| Q2 FY2025 | Jun 30, 2025 | -$12.43M | – |
| Q1 FY2025 | Mar 31, 2025 | -$28.48M | – |
| Q4 FY2024 | Dec 31, 2024 | -$12.49M | – |
| Q3 FY2024 | Sep 30, 2024 | -$27.07M | – |
| Q2 FY2024 | Jun 30, 2024 | -$17.30M | – |
| Q1 FY2024 | Mar 31, 2024 | -$38.35M | – |
| Q4 FY2023 | Dec 31, 2023 | -$26.93M | – |
| Q3 FY2023 | Sep 30, 2023 | -$46.68M | – |
| Q2 FY2023 | Jun 30, 2023 | -$23.56M | – |
| Q1 FY2023 | Mar 31, 2023 | -$59.15M | – |
| Q4 FY2022 | Dec 31, 2022 | -$30.02M | – |
| Q3 FY2022 | Sep 30, 2022 | -$42.41M | – |
| Q2 FY2022 | Jun 30, 2022 | -$47.07M | – |
| Q1 FY2022 | Mar 31, 2022 | -$64.45M | – |
| Q4 FY2021 | Dec 31, 2021 | -$53.83M | – |
| Q3 FY2021 | Sep 30, 2021 | -$43.44M | – |
| Q2 FY2021 | Jun 30, 2021 | -$37.21M | – |
| Q1 FY2021 | Mar 31, 2021 | -$58.25M | – |
| Q4 FY2020 | Dec 31, 2020 | -$39.84M | – |
| Q3 FY2020 | Sep 30, 2020 | -$47.16M | – |
| Q2 FY2020 | Jun 30, 2020 | -$31.08M | – |
| Q1 FY2020 | Mar 31, 2020 | -$31.61M | -111.4% |
| Q4 FY2019 | Dec 31, 2019 | -$26.79M | – |
| Q3 FY2019 | Sep 30, 2019 | -$30.14M | – |
| Q2 FY2019 | Jun 30, 2019 | -$15.97M | – |
| Q1 FY2019 | Mar 31, 2019 | $278.30M | – |
| Q4 FY2018 | Dec 31, 2018 | -$5.41M | – |
| Q3 FY2018 | Sep 30, 2018 | -$11.69M | – |
See a number that looks wrong?